Accustem Sciences (ACUT) Non-Current Debt (2022 - 2025)
Accustem Sciences (ACUT) posted quarterly Non-Current Debt of $22546.0 for Q4 2025, down 10.35% year-over-year from $25148.0 in Q4 2024, and down 49.55% quarter-over-quarter from $44689.0 in Q3 2025.
Accustem Sciences (ACUT) Non-Current Debt (2022 - 2025) Analysis & Trends
Accustem Sciences (ACUT) has reported Non-Current Debt for 4 consecutive years, with $22546.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt fell 10.35% year-over-year to $22546.0; the TTM figure through Dec 2025 stood at $22546.0 (down 10.35% YoY), while the FY2025 annual figure was $22546.0, down 10.35% from the prior year.
- Non-Current Debt eased to $22546.0 in Q4 2025 per ACUT's latest filing, from $44689.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $321760.0 in Q2 2022 and bottomed at $22546.0 in Q4 2025.
- Historically, Non-Current Debt has averaged $117025.8 across 4 years, with a median of $73826.0 in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt decreased 7.42% — and 2024, when it slumped 72.73%.
- Accustem Sciences' Non-Current Debt stood at $106551.0 in 2022, then tumbled by 47.74% to $55679.0 in 2023, then plunged by 54.83% to $25148.0 in 2024, then dropped by 10.35% to $22546.0 in 2025.
- Business Quant data shows ACUT's Non-Current Debt at $22546.0 in Q4 2025, $44689.0 in Q3 2025, and $66435.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Accustem Sciences | 3.54 Mn | 3.52 Mn | - | 62,641.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,546.00 |
| Sep 30, 2025 | 44,689.00 |
| Jun 30, 2025 | 66,435.00 |
| Dec 31, 2024 | 25,148.00 |
| Sep 30, 2024 | 57,597.00 |
| Jun 30, 2024 | 81,217.00 |
| Dec 31, 2023 | 55,679.00 |
| Sep 30, 2023 | 112,752.00 |
| Jun 30, 2023 | 297,880.00 |
| Dec 31, 2022 | 106,551.00 |
| Sep 30, 2022 | 212,056.00 |
| Jun 30, 2022 | 321,760.00 |